|
Fri, 10/24/2025 - 16:57 |
Sobi showcases new data across rare inflammatory conditions at ACR 2025 |
Swedish Orphan ... |
|
Tue, 10/21/2025 - 17:55 |
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report |
Swedish Orphan ... |
|
Tue, 10/21/2025 - 17:54 |
Sobi Q3 2025 report: Accelerated growth and portfolio momentum |
Swedish Orphan ... |
|
Sat, 09/20/2025 - 00:02 |
Tryngolza (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) |
Swedish Orphan ... |
|
Wed, 07/16/2025 - 05:31 |
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum |
Swedish Orphan ... |
|
Tue, 07/15/2025 - 15:35 |
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes |
Swedish Orphan ... |
|
Thu, 05/29/2025 - 17:46 |
Sobi to share new clinical data and research at EULAR 2025 |
Swedish Orphan ... |
|
Tue, 04/29/2025 - 06:52 |
Sobi publishes Q1 2025 report: Portfolio continues to deliver |
Swedish Orphan ... |
|
Wed, 04/23/2025 - 05:27 |
Sobi presents clinical data at WFH 2025 Comprehensive Care Summit |
Swedish Orphan ... |
|
Wed, 03/19/2025 - 03:52 |
Sobi announces a new research collaboration on the development of Gamifant (emapalumab) in sepsis, which is to be presented at the ISICEM congress |
Swedish Orphan ... |
|
Thu, 02/27/2025 - 04:39 |
US FDA grants Priority Review to Sobis supplemental Biologics Licence Application (sBLA) for Gamifant (emapalumab-lzsg) |
Swedish Orphan ... |
|
Thu, 02/20/2025 - 04:33 |
EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN |
Swedish Orphan ... |
|
Wed, 06/19/2024 - 02:45 |
European Commission grants Sobi Marketing Authorisation for ALTUVOCT for treatment of haemophilia A |
Swedish Orphan ... |
|
Wed, 06/12/2024 - 06:16 |
Sobi to present new data across its haematology portfolio at the 2024 EHA congress |
Swedish Orphan ... |
|
Thu, 02/08/2024 - 07:08 |
Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024 |
Swedish Orphan ... |
|
Thu, 02/07/2019 - 10:29 |
Sobi presents comprehensive study data on extended half-life haemophilia treatments at EAHAD |
Swedish Orphan ... |
|
Thu, 11/29/2018 - 06:57 |
Sanofi builds focus on rare blood disorders and cancers |
Genzyme |
|
Tue, 11/13/2018 - 01:14 |
AstraZeneca to divest US Synagis rights to Sobi |
AstraZeneca |
|
Tue, 04/17/2018 - 09:42 |
Grifols donates over 25 million international units of blood clotting factor in 2017 |
Grifols |
|
Mon, 04/17/2017 - 09:54 |
Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program |
Grifols |
